Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari (oral glutamine)
Emmaus Life Sciences, Inc. announced today that the company’s Marketing Authorization Application (MAA) for Xyndari has been fully validated and is now under assessment by the European Medicines Agency (EMA) for the treatment of sickle cell disease.
“Sickle cell disease patients in the European Union have not had access to new therapies for almost 20 years,” said Yutaka Niihara, MD, MPH, CEO and chairman of Emmaus. “The submission of this application reflects our continued commitment to provide treatment options for this painful and life-threatening disease to as many patients as possible.”
The MAA is supported by data from the company’s phase 3 randomized, double-blind, placebo-controlled, multi-center clinical trial of 230 patients ages 5 to 58 years old with sickle cell disease who had two or more painful crises within 12 months prior to enrollment. Patients who were treated with Xyndari over a 48-week period experienced fewer crisis episodes compared to patients who received a placebo (median 3 vs. median 4), fewer hospitalizations for sickle cell pain (median 2 vs. median 3), and fewer days in the hospital.
+myBinderRelated Content
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
-
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Diseasehttps://www.youtube.com/watch?v=CWTW5pDP...
-
Sickle cell cure is real, as this Kansas patient provesIntense pain. Fatigue. Repeated infectio...
-
Prevention of acute sickle cell crisis: review of the NEJM reportA recent article in the New England Jour...
-
Medical and Surgical Complications of Sickle Cell AnemiaThis book is a wide-ranging guide to the...
-
Sickle cell disease cure in sights of UAB Stem Cell InstituteTim Townes has a dream. He has a dream t...
-
HHS Secretary Alex Azar Touts White House Efforts to Fight Sickle Cell DiseaseBy 2029, Americans with sickle cell dise...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.